Risk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine.

ABSTRACT:

Background

OnabotulinumtoxinA demonstrates effectiveness in chronic migraine prevention but is hindered by variable patient responses. This study aims to identify modifiable and non-modifiable risk factors influencing the response to onabotulinumtoxinA.

Methods

We conducted a retrospective cohort study at a tertiary hospital involving chronic migraine patients treated with onabotulinumtoxinA. Data on risk factors and patient perceptions were collected through medical records and questionnaires.

Results

A total of 131 patients were included. At 12 months, a significant reduction in headache frequency was observed: from 26 episodes pre-treatment to 13 at 3 months, 12 at 6 months, 11 at 9 months, and 10 at 12 months. A third of patients stopped overusing medication after

SUBMITTER: Mendes-Andrade L 

PROVIDER: S-EPMC11864016 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature